AzTrials
AzTrials

Type 2 DiabetesDESCENDANCENCT01727349

Validation of a Predictive Risk Equation for Type 2 Diabetes in Families With Risk

A study testing HbA1c measurement and Oral Glucoce Tolerance Test in people with Type 2 Diabetes, run by Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète at 17 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Considering its epidemic-like development worldwide, associated with modifications in lifestyle, as well as its enormous social and economic weight, the prevention of type II diabetes is certain to be a central concern of health systems within the developed countries in the decades to come. Read more about this study

Who is it for?
Ages 25 years and olderHealthy volunteers can take part
Conditions the study is for
Type 2 Diabetes
What is being tested?
HbA1c measurement and Oral Glucoce Tolerance Test
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,035 participants
Where
17 sitesin 2 countries
Study dates
14 Dec 2011to 24 Nov 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Families at risk for diabetes defined by the existence of the disease in two successive generations and consists with healthy subject in the two generations.
  • Subjects must be aged over 25 years

Who cannot join

  • subject refusing to participate
  • pregnant women

Trial locations and contacts

17 sites in 2 countries.

17 sites in 2 countries

France16 sites
  • CHU Jean Minjoz

    Besançon, 25030

  • CHU Avicenne

    Bobigny, 93000

  • CHU de Bondy

    Bondy

  • CHU de BREST

    Brest

  • CHU de Caen

    Caen, 14000

  • CH Sud Francilien

    Évry, 91000

  • University Hospital Grenoble

    Grenoble, 38043

  • CHU de Bicetre

    Le Kremlin-Bicêtre, 94270

  • CHRU Lille

    Lille, 59037

  • CHU Marseille Hôpitaux Sud

    Marseille, 13274

  • CHU de Nancy

    Nancy, 54500

  • CHU de Nantes

    Nantes, 44000

  • CHU Bichat

    Paris, 75877

  • CHU de REIMS

    Reims

  • Centre Hospitalier Strasbourg

    Strasbourg, 67000

  • CHU Toulouse

    Toulouse, 31403

Other trials in France

Belgium1 site
  • CHU Sart Tilman Liège

    Liège, 4000

Other trials in Belgium

About this study

Official title: Validation of a Predictive Risk Equation for Type 2 Diabetes in Children With Diabetes to Achieve a Predictive Diagnostic Biochip for the Early Detection of Individuals at Risk in Families.

Considering its epidemic-like development worldwide, associated with modifications in lifestyle, as well as its enormous social and economic weight, the prevention of type II diabetes is certain to be a central concern of health systems within the developed countries in the decades to come. However, while simple obesity concerns the entire population, type 2 diabetes affects only one sub-population at high genetic risk. To be effective and realistic in economic terms, efforts at prevention must be thus targeted towards these subjects at high risk. The key issue involves identifying such subjects early enough so that a strategy of effective prevention can be organized in good time.

Until now, efforts have been concentrated on individuals at risk for diabetes readily identifiable within the general population, typically subjects in the second half of adulthood, presenting abdominal obesity and mild abnormalities of blood sugar. Preventive lifestyle and dietary measures are proposed but are constrictive and difficult to maintain over time, and the results, although they may be significant, remain disappointing, with mere postponement of an outcome which at this stage appears inevitable. The reason is ascribable to excessively tardy intervention, when the pathogenic process has already been ongoing for some ten years and the endocrine function of the pancreas is probably already irreparably impaired.

Read more

The alternative thus is earlier intervention, in childhood, adolescence or early adulthood. The problem is to identify individuals at high risk of becoming diabetic at a time when they are presenting no simple clinical or laboratory abnormalities allowing easy diagnosis. The familial character of type 2 diabetes is now well established, and future diabetic subjects are themselves above all the children of diabetic subjects. However, the prevalence of the disease among the descendants of type 2 diabetic subjects is around 20-30% and predictive tools are needed to combat diabetes in these high-risk families.

We propose to create a risk equation using an algorithm to reliably predict children most likely to develop diabetes later in life.

The algorithm will include 3 classes of data:

  • The genotype stemming from the genetic characterization of individuals and those their parents;
  • Environmental data concerning childhood, especially eating habits and physical activity;
  • Data of the mother who was eventually diabetic during pregnancy.

From a methodological standpoint, it would be rather difficult to take blood samples from children and wait some 50 years to determine whether or not they develop diabetes. To circumvent this difficulty, we will recruit subjects in families with a history of type II diabetes:

  • Parents alive, including at least one type 2 diabetic subject
  • Adult children (aged over 35 years), some of whom are already presenting type II diabetes, and healthy brothers and sisters, who form the control population. Test will be done to determine whether healthy subjects are really safe from the risk of diabetes (HbA1c measurement and glucose load test).

The Descendence study will include 500 families at risk involving about 3000 subjects (1000 subjects with diabetes and 2000 healthy subjects). It is expected to answer the following question: for a child born in such families at risk, what is the probability of developing diabetes later in life, so that early preventive action may be taken

Conditions
Type 2 Diabetes
Being tested
HbA1c measurement, Oral Glucoce Tolerance Test
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • HbA1c measurementOther

  • Oral Glucoce Tolerance TestOther

    Oral Glucoce Tolerance Test

Study groups in NCT01727349
Study groupRoleWhat they receive
Type 2 diabetic subjectOtherSubject with type 2 diabetes
Receives: Other: HbA1c measurement
healthy subjectOtherHealthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations
Receives: Other: Oral Glucoce Tolerance Test

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measure of risk of developing type 2 diabetes in at-risk families

    Oral Glucose Tolerance Test (only for health volunteers) HbA1c assay (for type 2 diabetic subject)

    Measured: participants will be followed from the moment where they sign consent form and until they have sent back questionnary and done the blood test, an expected average of 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Nov 2012 (estimated)
  2. Study start14 Dec 2011
  3. Primary completion24 Nov 2020
  4. Study completion24 Nov 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,035 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01727349
Sponsor's protocol ID
2011-A00686-35
Acronym
DESCENDANCE
Status last verified
Aug 2020
First submitted
8 Nov 2012
Last updated
11 May 2021
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing HbA1c measurement and Oral Glucoce Tolerance Test in people with Type 2 Diabetes, run by Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète at 17 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 May 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 17 sites in France, Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measure of risk of developing type 2 diabetes in at-risk families (time frame: participants will be followed from the moment where they sign consent form and until they have sent back questionnary and done the blood test, an expected average of 4 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in